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Several studies indicate that body fat and visceral 
adipose tissue in obese children and adolescents are 
predictive of obesity‑related comorbidities including 
CVD and insulin resistance (IR).[4,5] Furthermore, 
IR is the most important denominator for most of 
the obesity‑related metabolic and cardiovascular 
complications. Its most important consequence 
is type 2 diabetes mellitus, a disease which has 
been considered a serious public health problem 
affecting children as young as 6‑year‑old, mostly 
obese ones.[6,7]
Evidences indicated that in obese patients, inflammation, 
oxidative damage, and IR are the suggested main factors 
which increase the risk of CVD and diabetes.[8] In addition, 
INTRODUCTION
Childhood obesity has been considered an emerging 
health problem during the recent century.[1] The 
prevalence of obesity among children and adolescents 
has increased dramatically during the last decades.[1] 
It is associated with serious consequences and related 
comorbid disease at an early age. Moreover, most of 
the noncommunicable diseases in adulthood including 
cardiovascular disease (CVD) are originated from early 
life.[2,3] Hence, prevention and management of obesity, 
as a major risk factor for mentioned complications, is 
crucial.
Background: Considering the increasing trend of obesity, especially in developing countries such as Iran, and the role of inflammatory 
factors and insulin resistance (IR) in the occurrence of obesity‑related complications as well as the safety of some agents such as 
folic acid and metformin, this clinical trial was designed to investigate the effect of metformin and folic acid on inflammatory factors 
and IR among obese children. Materials and Methods: In this randomized, double‑blind, controlled clinical trial study, sixty 
obese children aged 6–12 years were enrolled. Selected obese children were randomly allocated in two interventional (1 mg/daily 
folic acid or 1000  mg metformin for 8  weeks) groups. Biochemical measurements including homeostasis model assessment of 
IR  (HOMA‑IR), homocysteine  (Hcy), tumor necrosis factor‑alpha  (TNF‑α), interleukin‑6  (IL‑6), and interleukin‑8  (IL‑8) were 
measured between and within the groups before and after trial. Results: In each group, thirty obese children were studied. The groups 
were age‑ and sex‑matched. After folic acid and metformin administration, mean of Hcy, HOMA‑IR, TNF‑α, and IL‑8 decreased 
significantly (P < 0.05). IL‑6 decreased significantly after folic acid use (P < 0.05).   Conclusion: The findings of this trial indicated that 
both metformin and folic acid could decrease IR and level of Hcy in obese children and adolescents. The effectiveness of metformin on 
IR was more significant than folic acid. Regarding the effectiveness of the two studied agents on inflammatory factors, it is suggested 
that the role of folic acid was superior to metformin. It is suggested that metformin is a proper agent for obese children with IR and 
folic acid is an appropriate supplement for obese children with increased inflammatory factors.
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there are many clinical and experimental evidences which 
indicate that reducing oxidative stress and inflammation in 
obese patients could have a significant effect on limiting the 
burden of obesity‑related complications including diabetes 
and CVD.[9,10]
It seems that using pharmacological approach for 
targeting the inflammatory pathway or reducing IR 
would be a novel strategy of controlling and reducing 
obesity‑related complications among pediatric population 
and consequently in adulthood.[11,12]
Although there are limited pharmacotherapy options for 
the treatment of pediatric obesity, some evidences mostly 
from clinical trials among adult population show that 
some pharmacological agents such as metformin and folic 
acid could have improving effect on the inflammatory 
status and IR of obese patients.[13‑15] There are few studies 
among pediatric populations in this regards and also, 
there are no conclusive reports regarding the appropriate 
duration of medical therapy with the above‑mentioned 
agents.[16,17]
Considering the increasing trend of obesity, especially 
in developing countries such as Iran,[18] and the role 
of inflammatory factors and IR in the occurrence of 
obesity‑related complications as well as the safety of the 
above‑mentioned agents, this clinical trial was designed 
to investigate the effect of metformin and folic acid on 
inflammatory factors and IR among obese children.
MATERIALS AND METHODS
In this randomized, double‑blind, controlled clinical trial 
study, sixty obese children, aged 6–12 years, attended the 
endocrinology clinic, affiliated to Shahrekord University of 
Medical Sciences, were enrolled.
Children with body mass index (BMI) >95th percentile 
were included in the study. Those with secondary obesity 
(due to endocrine disorder or genetic syndromes), renal 
and hepatic dysfunction, history of using anticonvulsant 
agents, estrogen, thiazides, metformin, cholestyramine, 
methotrexate, fibrates, nicotinic acid, and vitamin 
supplement (1 month before study) were excluded. In 
addition, those who were underweight, lost diet, or had 
not appropriate cooperation and regular follow‑up were 
also excluded.
The protocol of the study was approved by the Pediatrics 
Review Board and Regional Bioethics Committee of 
Shahrekord University of Medical Sciences. The study was 
registered in the Iranian Registry of Clinical Trials (IRCT), 
IRCT registration number (2014020116435N1). Written 
informed consent was obtained from all the selected patients 
or their parents after explanation of the methods and goal 
of the study.
Selected obese children were randomly allocated into 
two interventional (folic acid 1 mg/daily or metformin 
1000 mg/daily) groups [Figure 1].
• Folic acid (1 mg) supplied by Rouz Darou Pharmaceutical 
Company, Tehran, Iran
• Metformin (500 mg) supplied by Chemidarou industrial 
Company, Tehran, Iran.
All patients were examined clinically and their 
demographic and anthropometrics (BMI) information 
was recorded by a trained nurse using a questionnaire. 
The level of homocysteine (Hcy), IR, interleukin‑6 (IL‑6), 
interleukin‑8 (IL‑8), and tumor necrosis factor‑alpha (TNF‑α) 
were measured in all participants before and after trial.
The levels of biochemical measurements before and after 
trial between and within the groups were compared.
Laboratory measurements
Venous blood samples were obtained from each participant 
after overnight fasting.
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Assessed for eligibility (n = 73)
Excluded (n = 4)
Not meeting inclusion criteria
  (n = 2)
Refused to participate (n = 3)
Other reasons (n = 4)
Randomized (n = 60)
Allocated to and received 
intervention with folic acid
1 mg/daily (n = 30)
Allocated to and received 
intervention with metformin 
1000 mg/daily (n = 30)
Lost to follow-up (n = 0)
Discontinued intervention 
(n = 0)
Lost to follow-up (n = 0) 
Discontinued intervention 
(n = 0)
Analyzed (n = 30) Analyzed (n = 30)
Figure 1: Consort diagram of the study
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Hcy was measured by immunoassay method using 
Axis‑Shield Diagnostics (Dundee, UK) kit.
TNF‑α, IL‑6, and IL‑8 were measured enzymatically with 
standard auto‑analyzer kits (Pars Azmoon, Tehran, Iran).
IR was measured using homeostasis model assessment 
of IR (HOMA‑IR) formula (HOMA‑IR = fasting 
insulin [µU/mL] × fasting glucose [mg/dL]/405). 
Statistical analysis
Data were analyzed using SPSS version 20 (SPSS Inc., 
Chicago, IL, USA). Normality of data distribution was 
evaluated with Kolmogorov–Smirnov test. Mean of the 
studied variables before and after the study and between the 
groups was compared using paired t‑test and independent 
samples t‑test. The differences were considered as 
significant at P < 0.05.
RESULTS
In this trial, sixty obese children were allocated in two 
interventional groups (thirty obese children in each group). 
Demographic characteristics of the studied populations 
in the two groups are shown in Table 1. The two groups 
were age‑ and sex‑matched, and the mean of BMI was not 
significantly different (P > 0.05).
Mean ± standard deviation (SD) of biochemical 
measurements including Hcy, HOMA‑IR, IL‑6, IL‑8, and 
TNF‑α in the studied groups before and after the trial is 
shown in Table 2. Mean ± SD differences (before and after) of 
the studied biochemical variables in the two interventional 
groups are shown in Table 3.
There was not any significant relation between IR and Hcy 
and studied inflammatory factors (P > 0.05).
DISCUSSION
In this study, the effectiveness of folic acid and metformin 
on reducing inflammation and IR of obese children and 
adolescences was investigated. The results of the current 
study indicated that both metformin and folic acid could 
have an improving effect on IR and some inflammatory 
factors such as TNF‑α, IL‑8, and Hcy. Folic acid could 
significantly reduce the level of IL‑6 whereas metformin 
did not. Metformin have a superior effect on reducing IR 
and acid folic on reducing IL‑6.
Evidences indicated that the level of Hcy and inflammatory 
factors is higher in obese children and the increased level of 
both mentioned factors is associated with a higher risk of 
CVD in this group of population.[19,20] Hence, we hypothesize 
that if administration of the two studied agents, i.e., folic 
acid and metformin could decrease the level of Hcy and 
inflammatory factors, using these agents with lower side 
effects could have protective effect on the occurrence of 
CVD in this group of children.
Literature review in this regard indicated that there were 
few studies in this field among pediatrics population 
and there were no similar studies which compare the 
effectiveness of the two relatively safe pharmacological 
agents in this field.
Several studies have indicated the proper effect of metformin 
in the management of obese children, but regarding its 
anti‑inflammatory effects, there were few studies.[21,22] 
Results of different clinical trials on the effectiveness of 
metformin in childhood obesity were controversial in 
various fields of obesity management. Regarding the role 
of metformin in inflammation among obese children, the 
findings of different studies are also controversial.[23]
Gómez‑Díaz et al. have indicated that using 850 mg 
metformin for 12 weeks in 4–17‑year‑old children 
with glucose intolerance could have improving effect 
Table 1: Demographic characteristics of obese and 
overweight children in two studied groups (folic acid 1 
mg/daily and metformin 1000 mg/daily)
Variables Folic acid 1 mg/
daily (n=30)
Metformin 1000 mg/
daily (n=30)
P
Sex (female/male) 13/17 12/18 0.08
Age (years) 9.5±2.1 10.1±2.2 0.57
BMI (percentile) 94±3.7 95±2.5 0.87
BMI = Body mass index
Table 2: Mean±standard deviation of biochemical measurements including homeostasis model assessment of insulin 
resistance, homocysteine, tumor necrosis factor‑alpha, interleukin‑6, and interleukin‑8 in the two studied groups 
before and after trial
Variables Folic acid 1 mg/daily Metformin 1000 mg/daily
Before After P Before After P
HOMA‑IR 4.43±0.23 2.70±0.7 <0.001 5.12±3.81 2.32±0.8 <0.001
Hcy (µmol/L) 9.87±1.13 7.10±1.83 <0.001 10.72±2.7 7.19±2.41 <0.001
TNF‑α (pg/ml) 90.18±15.3 60.64±11.56 <0.001 93.66±20.43 67.56±12.91 0.002
IL‑8 (pg/ml) 111.30±22.81 90.78±14.18 0.001 110.18±23.16 86.68±11.42 0.002
IL‑6 (pg/ml) 338.39±25.12 294.21±23.76 0.001 326.17±24.75 328.76±31.16 0.89
HOMA‑IR = Model assessment of insulin resistance; Hcy = Homocysteine; TNF‑α = Tumor necrosis factor‑alpha; IL = Interleukin
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on HOMA‑IR and HbA1c, but no significant effect on 
inflammatory factors including TNF‑α, IL‑6, IL‑1α, and 
C‑reactive protein (CRP).[24]
Evia‑Viscarra et al. evaluated the effect of administration of 
1000 mg metformin for 3 months on inflammatory factors 
such as IL‑6, TNF‑α, and CRP among obese adolescents with 
IR. According to their results, metformin could significantly 
reduce IR and the level of TNF‑α.[25]
The effect of metformin use on Hcy level of obese children 
was not studied previously, and the results of adult studies 
in this field were different.[26,27]
In this study, metformin had a lowering effect on Hcy, IR 
and IL‑8, and TNF‑α, but it had no significant effect on IL‑6. 
In one study among adult diabetic patients, metformin had 
no significant effect on the level of IL‑6.
There are some studies which investigated the effect of folic 
acid on Hcy level and IR of obese population.[28,29] Studies 
among children population were scarce.
Solini et al. in Italy have investigated the effect of 
12‑week folic acid treatment on insulin sensitivity and 
some biochemical parameters such as Hcy and some 
inflammatory factors. After that period, Hcy decreased 
and insulin sensitivity increased significantly among obese 
adults.[30] They showed that folic acid use could reduce 
the circulating level of some inflammatory mediators 
independently of weight change. They concluded that 
folic acid could have a protective role for atherogenesis 
and CVDs in obese subjects.[30]
Peña et al. in Austria have indicated that administration 
of folic acid in obese children decreased the Hcy level.[31]
In a study in Greece, Papandreou et al. showed that oral 
folic acid could efficiently reduce the serum Hcy levels.[32]
Although evidences indicated that there is a link between 
inflammation and obesity and metabolic biomarkers such as 
HOMA‑IR in adult population, recent studies showed that 
the association was not similar for children and adolescents.[33]
In our trial, folic acid has a decreasing effect on all studied 
variables, especially on inflammatory factors.
Galcheva et al. have shown that though the level of HOMA‑IR 
was higher in obese prepubertal children, they did not find 
any association between TNF‑α and IL‑6 and adiposity.[34] In 
another study, Zabaleta et al. have not indicated a significant 
association between HOMA‑IR and TNF‑α and IL‑8.[33] Some 
studies also did not report any association between IL‑6 
and IR among children and adolescents. Roth et al. found 
a correlation between IL‑6 and HOMA‑IR score changes 
over 1 year in an intervention study on obese children.[35] 
Bugge et al. also did not demonstrate any cross‑sectional 
association between IL‑6 and HOMA‑IR, but they indicated 
that IL‑6 level at age 9 correlates with HOMA‑IR at age 
13 years, especially among girls.[36]
Similar to the previous studies, we did not find any 
association between HOMA‑IR and IL‑6, IL‑8, and TNF‑α 
in our studied obese children.
The limitation of the current study was shorter duration of 
the study. As this study was the first study in this field, we 
tried to design the trial for short duration and then plan future 
studies for longer duration and also in combination with 
lifestyle modification. In addition, it seems that the effect of 
studied agents in obese children with and without IR would 
be more helpful for proper management of childhood obesity.
The strength of this trial was its novelty, which compared 
the efficacy of the two relatively safe pharmacological agents 
for the treatment of pediatric obese population.
CONCLUSION
The findings of this trial indicated that both metformin 
and folic acid could decrease IR and level of Hcy in obese 
children and adolescents. The effectiveness of metformin 
on IR was more significant than folic acid. Regarding the 
effectiveness of the two studied agents on inflammatory 
factors, it is suggested that the role of folic acid was 
superior to metformin. These results could help us for 
proper management of obese children regarding their 
condition. It is suggested that metformin is a proper agent 
for obese children with IR, and folic acid is an appropriate 
supplement for obese children with increased inflammatory 
factors. Further studies with larger sample size and longer 
duration are recommended.
Table 3: Mean±standard deviation differences (before 
and after) of studied biochemical variables including 
homeostasis model assessment of insulin resistance, 
homocysteine, tumor necrosis factor‑alpha, interleukin‑6, 
and interleukin‑8 in the two interventional groups
Variables Folic acid 
1 mg/daily
Metformin 
1000 mg/daily
P
HOMA‑IR −2.13±0.99 −3.87±1.71 <0.001
Hcy (µmol/L) −2.71±3.01 −3.53±4.12 0.38
TNF‑α (pg/ml) −29.53±68.44 −31.38±51.63 0.90
IL‑8 (pg/ml) −20.51±30.39 −23.49±38.80 0.74
IL‑6 (pg/ml) 44.18±48.75 2.59±101.19 0.002
HOMA‑IR = Model assessment of insulin resistance; Hcy = Homocysteine; 
TNF‑α = Tumor necrosis factor‑alpha; IL=Interleukin
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